Učitavanje...

Evolution of melanoma cross-resistance to CD8(+) T cells and MAPK inhibition in the course of BRAFi treatment

The profound but frequently transient clinical responses to BRAF(V600) inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent B...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Pieper, Natalia, Zaremba, Anne, Leonardelli, Sonia, Harbers, Franziska Noelle, Schwamborn, Marion, Lübcke, Silke, Schrörs, Barbara, Baingo, Jolanthe, Schramm, Alexander, Haferkamp, Sebastian, Seifert, Ulrike, Sucker, Antje, Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Schilling, Bastian, Paschen, Annette, Zhao, Fang
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136878/
https://ncbi.nlm.nih.gov/pubmed/30221038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1450127
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!